Peter Curtin

Title(s)Professor Of Clinical, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UC San Francisco, San Francisco, CA06/1985Hematolgy & Oncology
    NC Memorial Hospital (UNC), Chapel Hill, NC06/1982Internal Medicine
    SUNY Upstate, Syracuse, NYMD06/1979Medicine

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    REGULATION OF ERYTHROPOIETIN GENE EXPRESSION
    NIH R29DK044956May 1, 1992 - Apr 30, 1997
    Role: Principal Investigator
    STRUCTURE &FUNCTION OF A UNIQUE B-THALASSEMIA DELETION
    NIH K11HL002060Apr 1, 1988 - May 31, 1993
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 Aug 25; 145:107565. Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, Blackmon A, Agrawal V, Pourhassan H, Amanam I, Arslan S, Otoukesh S, Sandhu K, Aldoss I, Ali H, Salhotra A, Al Malki MM, Artz A, Becker P, Smith E, Stein A, Marcucci G, Forman SJ, Curtin P, Nakamura R, Pullarkat V. PMID: 39208597.
      View in: PubMed   Mentions:
    2. Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Aug 15. Otoukesh S, Yang D, Mokhtari S, Pourhassan H, Agrawal V, Arslan S, Amanam I, Ball B, Koller P, Salhotra A, Sandhu K, Aribi A, Artz A, Aldoss I, Pullarkat V, Ali H, Blackmon A, Becker P, Curtin P, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. PMID: 39147891.
      View in: PubMed   Mentions:    Fields:    
    3. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 Aug 08. Arslan S, Desai A, Yang D, Mokhtari S, Tiemann K, Otoukesh S, Samara Y, Blackmon A, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Aribi A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. PMID: 39122188.
      View in: PubMed   Mentions:    Fields:    
    4. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. PMID: 38394770.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    5. CML and the WHO: Why? J Clin Oncol. 2024 Mar 20; 42(9):984-986. Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. PMID: 38086008.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1811-1821. Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. PMID: 37533373.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 08; 29(8):515.e1-515.e7. Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. PMID: 37182736; PMCID: PMC10527340.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring. Front Pharmacol. 2023; 14:1126981. Shen G, Moua KTY, Perkins K, Johnson D, Li A, Curtin P, Gao W, McCune JS. PMID: 37021042; PMCID: PMC10069443.
      View in: PubMed   Mentions: 2  
    9. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 06; 98(6):848-856. Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. PMID: 36880203.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 05; 29(5):314-320. Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. PMID: 36682470.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Extracorporeal photopheresis for the treatment of chronic graft versus host disease. Hematology. 2022 Dec; 27(1):785-794. Kansu E, Ward D, Sanchez AP, Cunard R, Hayran M, Huseyin B, Vaughan M, Ku G, Curtin P, Mulroney C, Costello C, Castro JE, Wieduwilt M, Corringham S, Ihasz-Davis A, Nelson C, Ball ED. PMID: 35802815.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Blood Adv. 2022 09 13; 6(17):4936-4948. Aldoss I, Yang D, Tomasian V, Mokhtari S, Jackson R, Gu Z, Telatar M, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz A, Aoun P, Gu D, Snyder D, Stewart FM, Curtin P, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat V, Nakamura R, Afkhami M. PMID: 35816633; PMCID: PMC9631622.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma. 2022 12; 63(13):3232-3236. Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. PMID: 36089918.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. Am J Hematol. 2022 05; 97(5):E171-E173. Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, Armenian S, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. PMID: 35132678.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw. 2022 02; 20(2):106-117. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. PMID: 35130502.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    16. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022 Feb 01; 128(3):529-535. Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Koller P, Ball B, Stewart F, Curtin P, Artz A, Nakamura R, Marcucci G, Forman SJ, Stein AS, Pullarkat V. PMID: 34633671.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    17. Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy. Blood Adv. 2020 10 13; 4(19):4798-4801. Aldoss I, Song JY, Curtin PT, Forman SJ. PMID: 33022063; PMCID: PMC7556138.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    18. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw. 2020 Sep 01; 1-4. Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. PMID: 32871558; PMCID: PMC9730290.
      View in: PubMed   Mentions: 16     Fields:    
    19. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 01; 18(1):12-22. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. PMID: 31910384.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    20. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 09; 16(9):1108-1135. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. PMID: 30181422.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    21. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biol Blood Marrow Transplant. 2018 06; 24(6):1119-1124. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. PMID: 29608957.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    22. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 12; 15(12):1520-1541. Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. PMID: 29223990.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    23. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. PMID: 27956535.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    24. Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21). Pathol Res Pract. 2015 Nov; 211(11):883-91. Nguyen JC, Kubik MJ, Broome HE, Curtin PT, Dell'Aquila ML, Wang HY. PMID: 26300063.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    25. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov; 12(11):1590-610. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. PMID: 25361806.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    26. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biol Blood Marrow Transplant. 2015 Jan; 21(1):89-96. Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT. PMID: 25445641.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    27. Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. J Community Support Oncol. 2014 Feb; 12(2):56-64. Wong-Sefdan I, Ale-Ali A, DeMoor PA, Martinez S, Curtin P, Lane T, Roeland E. PMID: 24971406.
      View in: PubMed   Mentions: 1     Fields:    
    28. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1150-63. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. PMID: 22510384; PMCID: PMC3404151.
      View in: PubMed   Mentions: 213     Fields:    Translation:Humans
    29. t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. Hum Pathol. 2011 Dec; 42(12):2029-36. Wang HY, Thorson JA, Broome HE, Rashidi HH, Curtin PT, Dell'Aquila ML. PMID: 21676437.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    30. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13; 2:20. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. PMID: 19439093; PMCID: PMC2694211.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    31. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008 Feb; 14(2):246-55. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. PMID: 18215785; PMCID: PMC2259225.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    32. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 01; 111(1):86-93. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. PMID: 17893227.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCellsCTClinical Trials
    33. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 01; 108(12):3674-81. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. PMID: 16902153; PMCID: PMC1895460.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCellsCTClinical Trials
    34. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May; 11(5):389-98. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Moseley AB, Bacigalupo A. PMID: 15846293.
      View in: PubMed   Mentions: 214     Fields:    Translation:HumansCellsCTClinical Trials
    35. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. Haematologica. 2004 Sep; 89(9):ECR30. Leis JF, Primack SL, Schubach SE, Curtin PT, Druker BJ, Maziarz RT. PMID: 15377482.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004 Apr; 45(4):695-8. Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT. PMID: 15160941.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    37. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis. Bone Marrow Transplant. 2002 Sep; 30(5):279-85. Hayes-Lattin BM, Curtin PT, Fleming WH, Leis JF, Stepan DE, Schubach S, Maziarz RT. PMID: 12209349.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001 Jul 15; 98(2):266-71. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF. PMID: 11435292.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    39. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood. 1995 May 15; 85(10):2735-41. Madan A, Lin C, Hatch SL, Curtin PT. PMID: 7742534.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    40. The inactive beta globin gene on a gamma delta beta thalassemia chromosome has a normal structure and functions normally in vitro. Blood. 1988 Mar; 71(3):766-70. Curtin PT, Kan YW. PMID: 3345345.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    Peter's Networks
    Concepts (192)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California